arrow
J

Jodi M. Carter

johns hopkins medicine
H指数:41
被引数:5,627

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
BREAST
IF7.9
2025-06-010
OAAI
Changes in breast cancer risk associated with benign breast disease from 1967 to 2013
2024-12-300
OAAI
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer
2024-06-100
OAAI
Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer

阻断肿瘤细胞内在PD-L1信号增强三阴性乳腺癌的AURKA靶向治疗

2024-05-301
OAAI
The spatially resolved single-cell atlas of the tumor immune architecture revealed the central role of IFN-alpha and plasmacytoid dendritic cells in triple-negative breast cancer in the Mayo Clinic cohort and FinXX trial
2024-05-020
PRE
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
2024-04-0228
PRE
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer
2023-04-1815
OAAI
Stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients
2023-03-013
PRE
Mitotic spindle hotspot counting using deep learning networks is highly associated with clinical outcomes in patients with early-stage triplenegative breast cancer who did not receive systemic therapy
2023-03-010
PRE
PDJ amplicon in triple negative breast cancer

PDJ扩增子在三阴性乳腺癌中的应用

2023-01-123
OAAI